New stage in evolution of drug treatment of pleural mesothelioma
نویسندگان
چکیده
For a long time, cytostatic therapy practically does not increase life expectancy than up to 18 months. The article describes the latest advances in development of drug treatment pleural mesothelioma and results CheckMate‑743 trial, which are turning point for malignant unresectable mesothelioma.
منابع مشابه
Diagnosis and treatment of malignant pleural mesothelioma.
There are three major challenges in the diagnosis of malignant pleural mesothelioma: mesothelioma must be distinguished from benign mesothelial hyperplasia; malignant mesothelioma (and its subtypes) must be distinguished from metastatic carcinoma; and invasion of structures adjacent to the pleura must be demonstrated. The basis for clarifying the first two aspects is determination of a panel of...
متن کاملDiagnosis and Treatment of Malignant Pleural Mesothelioma
There are three major challenges in the diagnosis of malignant pleural mesothelioma: mesothelioma must be distinguished from benign mesothelial hyperplasia; malignant mesothelioma (and its subtypes) must be distinguished from metastatic carcinoma; and invasion of structures adjacent to the pleura must be demonstrated. The basis for clarifying the first two aspects is determination of a panel of...
متن کاملPemetrexed in the treatment of malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a relatively uncommon tumor that is increasing in frequency in most areas of the world. For example, in the UK there has been a sharp increase in the number of cases since the late 1970s, a trend which is predicted to reach its peak by approximately 2015, when over 2000 cases per annum are likely to be diagnosed [1]. It is a tumor which is, in the vast ma...
متن کاملPleuropneumonectomy in the treatment of malignant pleural mesothelioma.
STUDY OBJECTIVES Malignant pleural mesothelioma (MPM) is predominantly a local/regional disease that results in a survival time that ranges from 4 to 12 months without treatment. Single-modality therapy using surgery, chemotherapy, or radiotherapy alone is largely ineffective. The objective of the study was presentation of the use of pleuropneumonectomy in a multimodality treatment setting and ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicinskij alfavit
سال: 2022
ISSN: ['2078-5631']
DOI: https://doi.org/10.33667/2078-5631-2022-26-27-30